Abstract
Flavopiridol is the first potent inhibitor of cyclin-dependent kinases (CDKs) to enter clinical trials. Little is known about mechanisms of resistance to this agent. In order to determine whether P-glycoprotein (Pgp) might play a role in flavopiridol resistance, we examined flavopiridol sensitivity in a pair of Chinese hamster ovary cell lines differing with respect to level of Pgp expression. The IC50s of flavopiridol in parental AuxB1 (lower Pgp) and colchicine-selected CHRC5 (higher Pgp) cells were 90.2 ± 6.6 nM and 117 ± 2.3 nM, respectively (P< 0.01), suggesting that Pgp might have a modest effect on flavopiridol action. Consistent with this hypothesis, pretreatment with either quinidine or verapamil (inhibitors of Pgp-mediated transport) sensitized CHRC5 cells to the antiproliferative effects of flavopiridol. Because of concern that colony forming assays might not accurately reflect cytotoxicity, we also examined flavopiridol-treated cells by trypan blue staining and flow cytometry. These assays confirmed that flavopiridol was less toxic to cells expressing higher levels of Pgp. Further experiments revealed that flavopiridol inhibited the binding of [3H]-azidopine to Pgp in isolated membrane vesicles, but only at high concentrations. Collectively, these results identify flavopiridol as a weak substrate for Pgp. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Arguello F, Alexander M, Sterry JA, Tudor G, Smith EM, Kalavar NT, Greene JF Jr, Koss W, Morgan CD, Stinson SF, Siford TJ, Alvord WG, Klabansky RL and Sausville EA (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91: 2482–2490
Bech-Hanson NT, Till JE and Ling V (1976) Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity. J Cell Physiol 88: 23–31
Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM and Bullock G (1994) Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 8: 465–475
Bible KC and Kaufmann SH (1996) Flavopiridol (NSC 649890, L86-8275): a cytotoxic flavone that induces cell death in human lung carcinoma cells. Cancer Res 56: 4856–4861
Bible KC and Kaufmann SH (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: importance of sequence of administration. Cancer Res 57: 3375–3380
Bible KC, Boerner SA, Kirkland K, Anderl KL, Duane Bartelt J, Svingen PA, Kottke TJ, Eckdahl S, Stalboerger PG, Jenkins RB and Kaufmann SH (2000) Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 6: 661–670
Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248
Bradshaw DM and Arceci RJ (1998) Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 16: 3674–3690
Brüsselbach S, Nettelbeck DM, Sedlacek H-H and Müller R (1998) Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 77: 146–152
Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E and Grever MR (1998) Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence upon functional p53. Blood 92: 3804–3816
Carlson BA, Dubay MM, Sausville EA, Brizuela L and Worland PJ (1996) Flavopiridol induces G1arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973–2978
Castro AF and Altenberg GA (1997) Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol 53: 89–93
Cole SP, Downes HF and Slovak ML (1989) Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer 59: 42–46
Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D and Di Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95: 9831–9836
Critchfield JW, Welsh CJ, Phang JM and Yeh GC (1994) Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol 48: 1437–1445
Czech J, Hoffmann D, Naik R and Sedlacek H-H (1995) Antitumoral activity of flavone L86-8275. Int J Oncol 6: 31–36
de Azevedo WF, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E and Kim S-H (1996) Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 93: 2735–2740
Dress M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA and Fiebig HH (1997) Flavopiridol (L86-8275): Selective antitumor in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 3: 273–279
Ford JM, Yang JM and Hait WN (1996) P-glycoprotein-mediated multidrug resistance: experimental and clinical strategies for its reversal. Cancer Treat Res 87: 3–38
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodear GM, Lieber M, Cossman J, Gottesman MM and Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116–124
Greenberger LM, Williams SS, Georges E, Ling V and Horwitz SB (1988) Electrophoretic analysis of P-glycoproteins produced by mouse J774.2 and Chinese hamster ovary multidrug-resistant cells. J Natl Cancer Inst 80: 506
Greenberger LM, Huang Yang C-P, Gindin E and Band Horwitz S (1990) Photoaffinity probes for the α1-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394–4401
Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268–2278
Kartner N, Evernden-Porelle D, Bradley G and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823
Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R and Sausville E (1992) Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 84: 1736–1740
Kaye SB (1998) Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. Curr Opin Oncol 10 Suppl: S15–S19
König A, Schwartz GK, Mohammad RM, Al-Katib A and Gabrilove JL (1997) The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90: 4307–4312
Lever J (1977) Active amino acid transport in plasma membrane vesicles from simian virus 40-transformed mouse fibroblasts. Characteristics of electrochemical Na+gradient-stimulated uptake. J Biol Chem 252: 1990
Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40: S3–S8
Losiewicz MD, Carlson BA, Kaur G, Sausville EA and Worland PJ (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 201: 589–595
Parker BW, Kaur G, Nieves-Neira W, Taimi M, Kohlhagen G, Shimizu T, Losiewicz MD, Pommier Y, Sausville EA and Senderowicz AM (1998) Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91: 458–465
Patel V, Senderowicz AM, Pinto D, Jr Igishi T, Raffeld M, Quintanilla-Martinez L, Ensley JF, Sausville EA and Gutkind JS (1998) Flavopiridol, a novel cyclin dependent kinase inhibitor, suppresses the growth of squamous cell carcinomas of the head and neck by inducing apoptosis. J Clin Invest 102: 1674–1681
Riordan JR, Deuchars K, Kartner N, Alon N, Trent J and Ling V (1985) Amplification of P-glycoprotein genes in multidrug- resistant mammalian cell lines. Nature 316: 817–819
Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL and Felsted RL (1987) Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884
Schlegel S, Klimecki W and List AF (1999) Breast cancer resistance protein (BCRP)-associated drug export and p53 inactivation impact flavopiridol (FLA) antitumor activity. Proc Am Assoc Cancer Res 40: 669
Schwartz GK, Farsi K, Maslak P, Kelsen DP and Spriggs D (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3: 1467–1472
Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A and Sausville E (1996) Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9: 1143–1168
Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG and Sausville EA (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986–2999
Sha EC, Sha MC and Kaufmann SH (1996) Evaluation of 2,6-diamino-N-([1-oxotridecyl)- 2-piperidinyl)methyl)-hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated in vitro. Invest New Drugs 13: 285–294
Van der Bliek AM, Van der Velde-Koerts T, Ling V and Borst P (1986) Overexpression and amplification of five genes in a multidrug-resistant chinese hamster ovary cell line. Mol Cell Biol 6: 1671–1678
Volm M (1998) Multidrug resistance and its reversal. Anticancer Res 18: 2905–2917
Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B and Williams J (1997) Cell-cycle arrest versus cell death in cancer therapy. Nature Med 3: 1034–1036
Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM and Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multi-drug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res 46: 5941–5946
Wright J, Blatner GL and Cheson BD (1998) Clinical trials of flavopiridol. Oncology 12: 1018–1024
Yang C-P, DePinho SG, Greenberger LM, Arceci RJ and Horwitz SB (1989) Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 264: 782
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boerner, S., Tourne, M., Kaufmann, S. et al. Effect of P-glycoprotein on flavopiridol sensitivity. Br J Cancer 84, 1391–1396 (2001). https://doi.org/10.1054/bjoc.2000.1688
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1688
Keywords
This article is cited by
-
Molecular pathogenesis and targeted therapeutics in Ewing sarcoma/primitive neuroectodermal tumours
Clinical Sarcoma Research (2012)
-
Genotyping panel for assessing response to cancer chemotherapy
BMC Medical Genomics (2008)